A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC

Clinical trial NCT06951464 · RECRUITING

Trial details

NCT number: NCT06951464
Sponsor: Sichuan University
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer

Start date: 2025-06-25
Primary completion: 2027-05-05
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.